科华生物(002022) - 2025 Q2 - 季度业绩预告

Estimated Performance for the Current Period The company projects a net loss for H1 2025, ranging from CNY 120 million to CNY 170 million, significantly wider than the prior year, with basic EPS also in deficit Estimated Financial Performance | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: CNY 120 million – CNY 170 million | Loss: CNY 52.4641 million | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: CNY 130 million – CNY 180 million | Loss: CNY 74.5405 million | | Basic Earnings Per Share | Loss: CNY 0.2333/share – CNY 0.3305/share | Loss: CNY 0.1035/share | Communication with Accounting Firm This performance forecast has not been audited by a certified public accountant - This performance forecast represents preliminary estimates by the company's finance department and has not been audited by a certified public accountant[2] Explanation of Performance Changes The company's year-on-year performance decline is primarily due to intensified market competition from policy changes impacting revenue and gross profit, and asset impairment provisions made under prudence principles, despite maintaining R&D and marketing investments Market Competition and Operational Impact Intensified market competition from industry-wide procurement, DRG implementation, and testing price adjustments led to declines in product demand, pricing, revenue, and gross profit, yet the company maintained R&D and marketing investments - Policy reforms including centralized procurement, DRG implementation, mutual recognition of test results, and price adjustments intensified market competition, leading to a year-on-year decline in the company's operating revenue and product gross profit[3] - Despite revenue decline, the company maintained R&D expense ratios and marketing resource investments at the same level as the prior year to solidify its development foundation[3] Impact of Asset Impairment Provisions Under the principle of prudence and considering industry and company specifics, the company recognized impairment provisions for accounts receivable, inventory, and fixed assets with potential impairment risks, negatively impacting current period profit - Based on the principle of prudence, the company recognized impairment provisions for accounts receivable, inventory, and fixed assets with potential impairment risks, adversely affecting profit[3] Future Outlook and Response Strategies Facing challenges, the company will pursue a 'comprehensive and refined' and 'integrated innovation' strategy, focusing on R&D, market expansion, lean management, and AI-driven digital transformation to foster new growth and enhance competitiveness - The company's strategic positioning is “comprehensive and refined” and “integrated innovation”, focusing on continuous R&D and marketing efforts to establish comprehensive multi-methodology solutions[4] - The company plans to accelerate its overseas market expansion and improve domestic and international sales and service channels to enhance product international competitiveness[4] - The company will enhance operational efficiency through lean management, cost reduction, efficiency improvement, and AI-driven digital transformation[4] Other Relevant Information The company emphasizes that this performance forecast is a preliminary estimate, with final financial data to be disclosed in the 2025 semi-annual report, urging investors to exercise caution - This performance forecast is a preliminary estimate, and specific financial data will be subject to the 2025 semi-annual report[5] - The company advises investors to make cautious decisions and be aware of investment risks[5]